JP2018531218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531218A5 JP2018531218A5 JP2018507641A JP2018507641A JP2018531218A5 JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- tautomer
- pharmaceutically acceptable
- acceptable salt
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- -1 hydroxyethyl group Chemical group 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005257 alkyl acyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510484124.6 | 2015-08-07 | ||
| CN201510484124 | 2015-08-07 | ||
| CN201510908082 | 2015-12-09 | ||
| CN201510908082.4 | 2015-12-09 | ||
| PCT/CN2016/092989 WO2017024968A1 (zh) | 2015-08-07 | 2016-08-03 | 作为fgfr和vegfr抑制剂的乙烯基化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531218A JP2018531218A (ja) | 2018-10-25 |
| JP2018531218A6 JP2018531218A6 (ja) | 2018-12-13 |
| JP2018531218A5 true JP2018531218A5 (enExample) | 2019-09-19 |
| JP6898306B2 JP6898306B2 (ja) | 2021-07-07 |
Family
ID=57983012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507641A Active JP6898306B2 (ja) | 2015-08-07 | 2016-08-03 | Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10519133B2 (enExample) |
| EP (1) | EP3333157B1 (enExample) |
| JP (1) | JP6898306B2 (enExample) |
| CN (1) | CN107922349B (enExample) |
| WO (1) | WO2017024968A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3584241B1 (en) * | 2017-02-14 | 2023-04-26 | FUJIFILM Corporation | Method for producing indazole compound, and indazole compound |
| CN111448185A (zh) * | 2017-12-07 | 2020-07-24 | 哈尔滨珍宝制药有限公司 | 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法 |
| CN113490667B (zh) * | 2018-12-29 | 2023-10-27 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物 |
| CN112752749B (zh) * | 2019-02-02 | 2021-07-16 | 南京明德新药研发有限公司 | 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物 |
| US12152013B2 (en) | 2019-02-02 | 2024-11-26 | Novaonco Js Therapeutics Co., Ltd. | Vinylpyridine carboxamide compound as PD-L1 immunomodulator |
| CN113993867B (zh) | 2019-06-14 | 2023-10-24 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的并环类化合物 |
| WO2021088859A1 (zh) * | 2019-11-06 | 2021-05-14 | 暨南大学 | 吲唑类化合物及其药用组合物和应用 |
| WO2021138391A1 (en) * | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4186894B1 (en) * | 2020-08-11 | 2024-12-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Fgfr inhibitor compound and use thereof |
| EP4262796A4 (en) * | 2020-12-17 | 2025-04-02 | Blossomhill Therapeutics, Inc. | MACROCYCLES AND THEIR USE |
| IL304014A (en) | 2020-12-30 | 2023-08-01 | Tyra Biosciences Inc | Indazole compounds as kinase inhibitors |
| CN116761798A (zh) * | 2020-12-30 | 2023-09-15 | 泰拉生物科学公司 | 作为激酶抑制剂的吲唑类化合物 |
| WO2023279041A1 (en) * | 2021-06-30 | 2023-01-05 | Tyra Biosciences, Inc. | Indazole compounds |
| IL317558A (en) * | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| CN116239623B (zh) * | 2022-11-18 | 2025-11-18 | 江西亚太科技发展有限公司 | 一种硼酸酯的制备方法及其应用 |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020010137A1 (en) * | 1997-09-18 | 2002-01-24 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2002022598A1 (en) | 2000-09-11 | 2002-03-21 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
| US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| JP4414881B2 (ja) | 2002-05-31 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾール化合物およびこれを含んでなる医薬組成物 |
| AU2003289287A1 (en) | 2002-12-03 | 2004-06-23 | Kyowa Hakko Kogyo Co., Ltd. | Jnk inhibitor |
| MXPA05006676A (es) * | 2002-12-19 | 2005-08-16 | Pfizer | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso. |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2007117465A2 (en) * | 2006-03-31 | 2007-10-18 | Abbott Laboratories | Indazole compounds |
| JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
-
2016
- 2016-08-03 CN CN201680046188.0A patent/CN107922349B/zh active Active
- 2016-08-03 US US15/750,704 patent/US10519133B2/en active Active
- 2016-08-03 EP EP16834592.4A patent/EP3333157B1/en active Active
- 2016-08-03 WO PCT/CN2016/092989 patent/WO2017024968A1/zh not_active Ceased
- 2016-08-03 JP JP2018507641A patent/JP6898306B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531218A5 (enExample) | ||
| KR102820455B1 (ko) | Shp2 활성 억제용 화합물의 제조 방법 | |
| JP2019524883A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2018528261A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2020529994A5 (enExample) | ||
| JP2016504387A5 (enExample) | ||
| JP2017507160A5 (enExample) | ||
| JP2016130266A5 (enExample) | ||
| JP2008505157A5 (enExample) | ||
| CN112771045A (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
| JP2020063289A5 (enExample) | ||
| JP2020500869A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2020128426A5 (enExample) | ||
| JP2006509842A5 (enExample) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| JP2017519796A5 (enExample) | ||
| JP2017508733A5 (enExample) |